The Latest Breaking News from Pfizer

US stock markets delivered stellar returns in the first half of the year and the Nasdaq 100 had its best first-half performance ever. However, Pfizer, whose COVID-19 vaccine made the company a household name recently fell to a 52-week low. Why is Pfizer stock going down and should you buy…

Pfizer (PFE) is spending its COVID-19 cash flows on meaningful growth avenues. However, given a recent downgrade, should value investors still be excited about this stock? Let’s look at the trends of its financial metrics to get an idea….

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Rivian’s strong sales results drove the unusual options activity in Friday trading. For those who aren’t enamored with the electric vehicle manufacturer’s business, there are, pardon the pun, other options.

Health officials are endorsing two new vaccines against respiratory syncytial virus (RSV) for older Americans, alongside flu and Covid-19 vaccines, although there are uncertainties about the risks

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

Vaccines to stave off the flu, a new COVID variant and now, respiratory syncytial virus could help avert another tripledemic this fall. Unless the public is too crisis-fatigued to care.

Participants could receive groundbreaking treatment after the Government signed an agreement with a leading pharmaceutical company.

Over the past twenty years, Lyme disease cases have continued to climb, and we are finally tantalizingly close to another vaccine.

Case brought against General Medical Council for failure to look into claimed links to heart problems and deaths

Pfizer and European pharmaceutical firms to stockpile vaccines for rapid response, raising concerns over equity